What is Amgen's IMDELLTRA/IMDYLLTRA — total revenues?

Amgen (AMGN) reported IMDELLTRA/IMDYLLTRA — total revenues of $258M in Q1 2026.

What does IMDELLTRA/IMDYLLTRA — total revenues mean?

This metric represents the total net sales generated from the commercialization of the Imdelltra (tarlatamab) therapeutic product line. It reflects the market adoption and clinical utilization of this specific oncology treatment within the company's broader biopharmaceutical portfolio. Tracking this revenue stream provides insight into the commercial success of the firm's recent product launches in the specialty medicine space.

Amgen AMGN IMDELLTRA/IMDYLLTRA — Total revenues

Other product segments

Repatha

$3.02B—

Other products

$1.53B+3.6%

Prolia

$727M-33.8%

EVENITY

$562M+27.1%

TEPEZZA

$490M+28.6%

Otezla

$431M-1.4%

BLINCYTO

$415M+12.2%

Nplate

$412M+31.6%

XGEVA

$411M-27.4%

TEZSPIRE

$343M+20.4%

KYPROLIS

$330M+1.9%

ENBREL

$320M-37.3%

Aranesp

$311M-8.5%

Vectibix

$287M+7.5%

UPLIZNA

$262M+188%

KRYSTEXXA

$255M+8.1%

Similar metrics at other companies

BIIBIMRALDI — Total Revenue

$49.6M+4.6%

PFEInlyta — Revenues:

$214M-2.3%

GILDTrodelvy — Total revenues

$402M+37.2%

SDGROncology, Neurology, and Immunology Product — Total revenues

$700K+16.7%

BMYRevlimid — Total Revenues

$349M-62.7%

SUPNTrokendi XR — Total revenues

$9.48M-26.0%

Other financials

Income statement

See full

Revenue$8.6B+5.8%

Gross profit$5.9B+13.4%

Operating income$2.7B+126%

Net income$1.8B+5.1%

EPS (diluted)$3.34+4.4%

Balance sheet

See full

Cash & equivalents$559.0M+10.0%

Total debt$57.3B-0.1%

Total equity$9.2B+48.1%

Total assets$92.5B+3.5%

Cash flow

See full

Operating cash flow$2.2B+57.4%

CapEx$712.0M+73.2%

Free cash flow$1.5B+50.7%

Valuation

See full

Market cap$193.39B+29.6%

Enterprise value$250.16B+22.1%

P/E24.8×+2.3×

P/S5.2×+0.9×

Profitability

See full

Gross margin68.3%+5.3pp

Operating margin28.4%+6.6pp

Net margin21%+3.6pp

FCF margin23.1%-8.9pp

Returns & leverage

See full

Return on equity101.3%-4.4pp

Debt / equity6.2×-3.0×

Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's imdelltra/imdylltra — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amgen's IMDELLTRA/IMDYLLTRA — total revenues?: Amgen (AMGN) reported IMDELLTRA/IMDYLLTRA — total revenues of $258M in Q1 2026.
What does IMDELLTRA/IMDYLLTRA — total revenues mean?: This metric represents the total net sales generated from the commercialization of the Imdelltra (tarlatamab) therapeutic product line. It reflects the market adoption and clinical utilization of this specific oncology treatment within the company's broader biopharmaceutical portfolio. Tracking this revenue stream provides insight into the commercial success of the firm's recent product launches in the specialty medicine space.